Business Wire

Q4 Inc. Releases Next Generation Investor Conference Features for its Rapidly Growing Investment Banking Client Base

9.12.2021 17:00:00 EET | Business Wire | Press release

Share

Q4 Inc. (TSX: QFOR) (“Q4" or “the Company”), a leading capital markets communications platform, today announced the release of a suite of new features for its Capital Markets Event (“CME”) platform, launched earlier this year, and designed to provide virtual and in-person events for investment banking hosted investor conferences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Branded Event Registration (Graphic: Business Wire)

Starting in 2020, Q4 has experienced unprecedented demand from investment banks to create, host and deliver investor conferences for their buy-side clients. Since that time, Q4 has hosted thousands of market participants across investor conferences, reverse roadshows and corporate investor days and has established the bar by which all other capital markets and financial service events are measured. Building on its rapidly expanding footprint in the investment banking market, Q4 continues to enhance the CME platform in its partnership with corporate access teams at the world’s leading investment banks.

New capabilities recently added include sophisticated event registration, easy scheduling for meetings of all sizes, whether they are 1:1, 2:1 or larger group meetings, and meeting management data and analytics to assist corporate access teams successfully envision, plan and execute these critical events. These new features are embedded within Q4’s event platform, as well as API integrated into Zoom, Microsoft Teams and other technologies, delivering a seamless conference experience for all participants.

Specifically, these new features provide new registration functionality, which allows corporate and investor participants to submit their availability, and allows investors to indicate which corporate issuers they are interested in meeting with in priority order and preference for 1:1, 2:1 or a larger group meeting. This information is directly funneled to the internal scheduling tool, which makes scheduling significantly easier and updates automatically as participant availability changes.

Additionally, the Platform has new features that allow for meeting details to be easily added, edited and made available to all participants so that everyone is easily informed about the type of meeting, attendee information, and easy links for meeting access.

Finally, this upgrade provides critical data around scheduling as well as session and meeting attendance, helping corporate access teams determine which corporate issuers and investors may need additional meetings to enrich their experience, and require priority focus.

“We launched our Capital Markets Events (CME) platform with the vision of connecting all capital markets participants in their discovery, communications and engagement with each other,” said Darrell Heaps, CEO of Q4. “We are excited to enhance the capabilities of our platform, and deliver an elevated experience for our investment bank customers. We will continue to add features to our rapidly evolving solution, as we lead the digital transformation of corporate access engagements that connect all sides of the capital markets.”

To learn more about the Q4 CME platform, click here.

About Q4, Inc.

Q4 Inc. (Q4), is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently discover, communicate, and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets customer relationship management solution, and shareholder and market analytics tools. The firm is a trusted partner to over 2,600 public companies as well as top tier investment banks. Q4 is based in Toronto, with offices in New York and London.

To learn more, visit: www.q4inc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Karen Greene media@q4inc.com

IR Inquiries:
Matt Tractenberg ir@q4inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye